Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies

EMVision Medical Devices Awarded $3m Grant to Expand Brain Scanner into Trauma Care
EMVision wins $3m federal grant to develop and test its portable brain scanner for traumatic brain injury, expanding beyond stroke detection.
Latest Stories — SECTOR DESK

Monash IVF Group Warns FY27 Profit Will Fall Well Below Expectations
Monash IVF warns FY27 profit will fall materially below FY26 and analyst expectations as weak treatment demand and rising costs squeeze earnings.

IDT Australia Forecasting Positive FY27 Operating Earnings After Strategic Reset
IDT Australia forecasts FY27 EBITDA of $1m–$1.5m as higher-value contracts drive revenue growth after its strategic reset.

Racura Oncology Demonstrates Key Equivalence for Reformulated Bisantrene Anti-Cancer Drug
Racura Oncology confirms reformulated bisantrene matches legacy drug exposure, supporting plans for a Phase 2b/3 AML trial.

Mayne Pharma Agrees to $604m Takeover Proposal from Gedeon Richter
Mayne Pharma agrees to Gedeon Richter’s $604m cash takeover at $6.40 a share—a 99.4% premium—with unanimous board backing.

Imricor Medical Systems Adds First US Hospital Customers for iMR Procedures
Imricor Medical Systems signs its first two US hospital customers for iMR cardiac procedures, marking a key step in commercialisation.

Artrya Signs Five-Year Deal with HonorHealth to Expand US Cardiac Imaging Reach
Artrya signs a five-year, US$0.5m minimum deal with HonorHealth, expanding its Salix cardiac imaging software across nine Arizona hospitals.

Clarity Pharmaceuticals Granted Breakthrough Therapy Designation for Prostate Cancer Copper Theranostic
Clarity Pharmaceuticals wins FDA breakthrough status for prostate cancer PET agent 64Cu-SAR-bisPSMA, a major milestone for its copper theranostic program.

BlinkLab Reports Positive Results from Smartphone-Based Study into Genetic Autism
BlinkLab reports positive SHANK2 autism study results, with its smartphone test detecting significant differences in brain and sensorimotor measures.

EVE Health Group Signs Australian Pharmacy Deal for Men's Health Range
EVE Health signs Australian pharmacy deal for its men’s health range, retaining 75% of distributable profit in a capital-light route to market.

Immutep Reports Exposure-Dependent Inhibition of T-Cell-Driven Responses in IMP761 Phase I Study
Immutep’s IMP761 showed significant, exposure-dependent suppression of T-cell responses in Phase I, with no serious or severe adverse events.

Mayne Pharma Sells International Operations for $55.5m to Focus on US Business
Mayne Pharma sells international operations for $55.5m, sharpening its focus on US Women’s Health, Dermatology and DistributeRx growth.